Dedicated to the
discovery, development,
manufacture, and
marketing
of innovative healthcare products.
Patient-centric and research-driven.
As a leading research-driven biopharmaceutical company, Boehringer Ingelheim puts patients first in everything we do. Patients inspire us in our mission to lead the science that creates breakthrough therapies. Our portfolio includes a range of world-class commercialized and developmental products in diabetes, oncology, respiratory, cardiology, immunology, and animal health.
With a deep understanding of molecular pathways, we are pioneering new ways to target, repair, and prevent many inflammatory diseases. Our researchers are hard at work on advances in hard-to-treat inflammatory diseases of the lung, gut, skin, and joints.
Over 37 years’ experience in biotechnology
You may not know us by name, but nearly two-thirds of the world’s 20 leading pharmaceutical companies trust Boehringer Ingelheim as a contract manufacturer of their proprietary biologic medicines. In fact, we are one of the largest producers of biologic medicines in the world.
Proudly made in the US.
Fremont, California, is the home of Boehringer Ingelheim’s rapidly growing US Biopharmaceuticals Business Unit. With a diverse team of over 500 people, we cover biopharmaceutical development and manufacturing from small scale to commercial, from drug substance manufacturing to fill/finish, packaging, and medical device assembly.
Family-owned since 1885.
We stand alone among the world’s top 20 pharmaceutical companies as the only privately held business. We don’t report to shareholders. That means we can make the choices we feel are right for the long term. One of those choices is investing in immunology.
At Boehringer Ingelheim, we believe in value through innovation
To us, that means listening, learning, and leading.
Value through innovation is what drives us to continuously search for innovative ways to improve the lives that we touch — whether that be the lives of patients and their families, our employees, or our community.
-
Listening to patients
What do patients and their caregivers need? We ask them, to make sure we’re delivering the right solutions.
-
Collaborating on research
Cancer research is a team effort. We work with the Sarah Cannon Research Institute, Yale University, and others to find answers.3-5
-
Sharing molecules
Our scientists developed opnMe.com to share well-characterized molecules with fellow researchers — so we can all get smarter together.1
-
Communicating with doctors
We participate in a multitude of medical conferences and communities to stay current with physician concerns.
-
Spreading knowledge
When people understand biosimilars, they’ll be onboard — that’s our belief. It’s why we helped found the Biosimilars Forum and other educational groups.2
-
Helping others
Making More Health helps micro-entrepreneurs around the world build and spread good ideas for local healthcare.6
We are proud of the role we play in raising public awareness of biosimilars and Interchangeable biosimilars, as well as the importance of stimulating a competitive marketplace to bring safe, effective, high-quality, and more affordable treatment options to patients in the US and worldwide
References:
-
1. Opnme website. https://www.opnme.com. Accessed July 20, 2021.
-
2. Biosimilars Forum website. https://biosimilarsforum.org/about-us/members. Accessed July 20, 2021.
-
3. Business Wire website. Boehringer Ingelheim expands collaboration with Sarah Cannon Research Institute to investigate novel immune-oncology combination therapy. https://www.businesswire.com/news/home/20171030005068/en/Boehringer-Ingelheim-expands-collaboration-Sarah-Cannon-Research. Published October 30, 2017. Accessed July 20, 2021.
-
4. Boehringer Ingelheim website. Boehringer Ingelheim and Yale University collaborate to investigate novel immunotherapy targets across several therapeutic areas. https://www.boehringeringelheim.com/press-release/boehringer-ingelheim-and-yale-university-collaborate-investigate-novel-immunotherapy. Published January 13, 2015. Accessed July 20, 2021.
-
5. Boehringer Ingelheim website. Boehringer Ingelheim expands collaboration with Vanderbilt University to tackle some of the most difficult-to-treat cancers. https://www.boehringer-ingelheim.us/press-release/boehringer-ingelheim-expands-collaboration-vanderbilt-university-tackle-some-most. Published March 2, 2017. Accessed July 20, 2021.
-
6. Making More Health website. The Making More Health initiative (MMH). https://www.makingmorehealth.org. Accessed July 20, 2021.